



Abstract submission guidelines

Please read this information carefully before proceeding to the online submission form.

IMPORTANT DATES

Submission deadline:	01 July 2024, 23:59 (CET)
Abstract review:	July 2024
Abstract notification:	July 2024

GENERAL

1. Please prepare your abstract in an extra e.g. Word-file before moving on to the online system. We recommend the outline in Question/Objective - Methods - Results - Conclusions. The number of characters is limited to 2,000 (including spaces).
2. Abstracts can only be submitted online via the online abstract submission form.
3. Abstracts must be submitted in English.
4. Please fill in the conflict of interest disclosure form before submitting your abstract and upload it while the submitting process.
5. Abstracts sent by post or email will not be accepted. No exceptions will be made.

DEFINITIONS

Submitting author:	Person who submits the abstract.
Presenting author:	Person who will physically present the abstract at the congress and who is marked as the presenter in the programme.
Corresponding author:	Person who will be included in all communications on the abstract.

PUBLICATION POLICY

We will publish all accepted abstracts in the virtual format of the “The Journal of Headache and Pain”. All accepted abstracts will be included in the online programme.

CONTACT US

General enquiries
headache-congress@conventus.de

Abstract management
abstract@conventus.de
+49 (0) 3641 31 16-161

Hosting society
European Headache Federation
www.ehf-headache.com

Conference co-chair
Professor Antoinette
Maassen van den Brink

Professor of Pharmacology
Dept. of Internal Medicine of Erasmus
University Rotterdam
Rotterdam, NL

Conference co-chair
Professor Jan Versijpt

Director Headache and Facial Pain
Clinic
Universitair Ziekenhuis Brussels
Brussels, BE

Congress organisation
Conventus Congressmanagement &
Marketing GmbH
Carl-Pulfrich-Strasse 1
07745 Jena/DE
www.conventus.de

Project managers:
Marlen Schiller & Andreas Lelle



TOPICS

- Animal models in headache research
- Human models in headache research
- Genetics | Genomics | RNA
- Neuroimaging in headache disorders
- CSF dynamics / glymphatic system and headache disorders
- Headache and metabolism / inflammation
- Preclinical research on novel pharmacological targets
- New clinical developments in prophylactic medications and acute medications
- CGRP (receptor) inhibitors in the clinic
- Devices, nerve blocks and non-pharmacological care
- Medication overuse
- Epidemiology & burden
- Data science and AI
- Aura and interictal symptoms
- Risk factors and comorbidities
- Sex and gender
- Regional differences in access to care
- Headache in children and adolescents
- Headache in the elderly
- Migraine
- Cluster headache & other TACs
- Oro-facial and temporomandibular disorders
- Posttraumatic headache disorders
- Secondary headaches
- Tension type headache
- Trigeminal neuralgia
- Chapter four primary headaches
- Miscellaneous / other topic

AFTER THE SUBMISSION

1. The reviewers will judge the abstracts according to the relevance to EHC 2024. They will assess the standard of English, objectivity of statements, description of the work, suitability of methods to aims, conclusions confirmed by objective results, ethics, scientific value, potential clinical value, originality of work and overall impression.
2. The submitting, presenting and corresponding authors will be notified by the end of August 2024, whether the abstract has been accepted. Notifications will be sent via email to the email address provided during submission. It is the authors' responsibility to ensure that emails from EHC 2024 can reach them.
3. The **presenting author must be a registered participant**. Please note that the presenting author is not automatically registered by submitting an abstract. Regular registration is obligatory and binding and implies payment of the registration fee. For registration, please click [here](#).

PRESENTATION OF ABSTRACTS

1. Abstracts can be accepted either as ePoster or oral presentations.
2. If your abstract is accepted as an ePoster, you will be requested to be available for discussion during the corresponding moderated poster session.
3. Oral presentations will be given further information on length of lecture and presentation details closer to the meeting.
4. Full presentation guidelines will be sent after the final allocation of abstracts to the programme.

Hosting society

European Headache Federation
www.ehf-headache.com

Conference co-chair

Professor Antoinette
Maassen van den Brink

Professor of Pharmacology
Dept. of Internal Medicine of Erasmus
University Rotterdam
Rotterdam, NL

Conference co-chair

Professor Jan Versijpt

Director Headache and Facial Pain
Clinic
Universitair Ziekenhuis Brussels
Brussels, BE

Congress organisation

Conventus Congressmanagement &
Marketing GmbH
Carl-Pulfrich-Strasse 1
07745 Jena/DE
www.conventus.de

Project managers:
Marlen Schiller & Andreas Lelle



RULES

Failure to observe these guidelines may result in your abstract not being accepted.

1	An abstract can be submitted to the EHC 2024 if it has been presented or published previously. However, this must be stated during submission.
2	The correct topic must be selected to ensure correct scoring. The content of the abstract must be topic related. The scientific committee reserve the right to re-categorise an abstract.
3	Abstracts must contain data and meet international ethical standards.
4	Abbreviations should be defined at first mention.
5	Trade names cannot be mentioned in the title. However, trade names in brackets will be accepted in the body of the text.
6	The presenter or one of the co-authors has a conflict of interest, this must be clearly stated (as per certification rules). An abstract cannot be accepted, if the "conflict of interest disclosure" has not been completed.
7	The abstract cannot contain more than 2,000 characters (approx. 250 words) – This count includes only the abstract itself (including blank spaces and punctuation) – not data of authors and any attachments.
8	The abstract must be structured into the following sections: Question/Objective; Methods; Results; Conclusions.
9	Please use single line spacing, type the text unjustified, without hyphenating words at line breaks. Use hard returns only to end headings and paragraphs, not to rearrange lines.
10	Greek and other special characters may be included. If you are unable to reproduce a particular special character, please type out the name of the symbol in full
11	SI units should be used throughout (litre and molar are permitted, however).
12	Web links (URLs) should be provided in full, including both the title of the site and the URL, in the following format: Mouse Tumour Biology Database [http://tumor.informatics.jax.org/cancer_links.html]
13	Tables should be numbered (e.g. Table 1) with a short, descriptive title (Short title, maximum one sentence).
14	Tables must be cited/called out in the text.
15	Tables should be formatted using the "Table function" in a word processing program to ensure that columns of data are kept aligned when the file is sent electronically. Tables should not be created with tabs or submitted as images. No colour or shading should be added
16	Figures and illustrations should be numbered (e.g. Figure 1) with a short, descriptive title. This text must form part of the text file and not the figure file. Figures must be cited/called out in the text. You must have all necessary permissions to use figures.
17	Figures must be supplied electronically in the body of the text at 300 dpi minimum. Each figure must be inserted as a single, composite file (parts must not be separate graphical units). Don't include figures with embedded hyperlinks.
18	Acknowledgements: Brief acknowledgements may be included and should be placed after Conclusions and before the References. If the abstract is being presented on behalf of a study group, this information should be noted here rather than in the author list.



19	For all abstracts that include details, images, or videos relating to an individual person, written informed consent for the publication of these details must be obtained from that person (or their parent or legal guardian in the case of children under 18) and must be stated within the abstract.
20	All references should be cited/called out consecutively in the text, using numbers in square brackets. Only papers that have been published, or are in press, or are available through public e-print/preprint servers should be included in the reference list.
21	References should be laid out at the end of the abstract in Vancouver style and be preceded by the relevant reference number.
22	Once the abstract is submitted, it can be re-edited and modified until the submission deadline (1 July 2024, 23:59 /CET). The submitting author will be required to create a user account. In order to log back into the portal, please make a note of the username and password created during the process.
23	If you have successfully submitted your abstract, you will receive a confirmation number. If no confirmation number is received, the abstract cannot be considered as successfully submitted and accepted.
24	If you leave the system without saving the abstract all data is lost. The submitted/draft abstracts cannot be edited after the submission deadline (1 July 2024, 23:59 /CET).
25	Please ensure that your abstract does not contain spelling, grammatical or scientific errors. No corrections are possible after the submission deadline. The abstract will be reproduced exactly as submitted. No proof reading will be completed.

Hosting society

European Headache Federation
www.ehf-headache.com

Conference co-chair

Professor Antoinette
Maassen van den Brink

Professor of Pharmacology
Dept. of Internal Medicine of Erasmus
University Rotterdam
Rotterdam, NL

Conference co-chair

Professor Jan Versijpt

Director Headache and Facial Pain
Clinic
Universitair Ziekenhuis Brussels
Brussels, BE

Congress organisation

Conventus Congressmanagement &
Marketing GmbH
Carl-Pulfrich-Strasse 1
07745 Jena/DE
www.conventus.de

Project managers:
Marlen Schiller & Andreas Lelle